1. Home
  2. IMVT vs SXI Comparison

IMVT vs SXI Comparison

Compare IMVT & SXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMVT
  • SXI
  • Stock Information
  • Founded
  • IMVT 2018
  • SXI 1955
  • Country
  • IMVT United States
  • SXI United States
  • Employees
  • IMVT N/A
  • SXI N/A
  • Industry
  • IMVT Biotechnology: Biological Products (No Diagnostic Substances)
  • SXI Industrial Machinery/Components
  • Sector
  • IMVT Health Care
  • SXI Industrials
  • Exchange
  • IMVT Nasdaq
  • SXI Nasdaq
  • Market Cap
  • IMVT 2.7B
  • SXI 2.3B
  • IPO Year
  • IMVT N/A
  • SXI N/A
  • Fundamental
  • Price
  • IMVT $15.24
  • SXI $210.48
  • Analyst Decision
  • IMVT Buy
  • SXI Strong Buy
  • Analyst Count
  • IMVT 11
  • SXI 4
  • Target Price
  • IMVT $35.88
  • SXI $223.50
  • AVG Volume (30 Days)
  • IMVT 1.2M
  • SXI 144.8K
  • Earning Date
  • IMVT 08-11-2025
  • SXI 07-31-2025
  • Dividend Yield
  • IMVT N/A
  • SXI 0.64%
  • EPS Growth
  • IMVT N/A
  • SXI N/A
  • EPS
  • IMVT N/A
  • SXI 4.64
  • Revenue
  • IMVT N/A
  • SXI $790,107,000.00
  • Revenue This Year
  • IMVT N/A
  • SXI $12.93
  • Revenue Next Year
  • IMVT N/A
  • SXI $7.01
  • P/E Ratio
  • IMVT N/A
  • SXI $43.39
  • Revenue Growth
  • IMVT N/A
  • SXI 9.64
  • 52 Week Low
  • IMVT $12.72
  • SXI $128.85
  • 52 Week High
  • IMVT $34.47
  • SXI $212.66
  • Technical
  • Relative Strength Index (RSI)
  • IMVT 43.58
  • SXI 74.06
  • Support Level
  • IMVT $14.50
  • SXI $198.47
  • Resistance Level
  • IMVT $15.52
  • SXI $207.24
  • Average True Range (ATR)
  • IMVT 0.69
  • SXI 6.02
  • MACD
  • IMVT -0.06
  • SXI 0.62
  • Stochastic Oscillator
  • IMVT 41.16
  • SXI 92.89

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

About SXI Standex International Corporation

Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.

Share on Social Networks: